Skip to Content

Everolimus

In the US, Everolimus (everolimus systemic) is a member of the following drug classes: mTOR inhibitors, selective immunosuppressants and is used to treat Brain Tumor, Breast Cancer, Neuroendocrine Carcinoma, Organ Transplant - Rejection Prophylaxis, Pancreatic Cancer, Renal Angiomyolipoma, Renal Cell Carcinoma, Subependymal Giant Cell Astrocytoma and Tuberous Sclerosis.

US matches:

UK matches:

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XE10,L04AA18

CAS registry number (Chemical Abstracts Service)

0159351-69-6

Chemical Formula

C53-H83-N-O14

Molecular Weight

958

Therapeutic Category

Selective immunosuppressant

Chemical Name

(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyetoxyl)-3-metoxycyclohexyl]-1-metyletyl]-10,21-dimetoxy-6,8,12,14,20,26-hexametyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone (WHO)

Foreign Names

  • Everolimusum (Latin)
  • Everolimus (German)
  • Évérolimus (French)
  • Everolimus (Spanish)

Generic Names

  • Everolimus (OS: USAN, BAN, JAN)
  • RAD 001 (Novartis) (IS)
  • SDZ-RAD (Novartis) (IS)

Brand Names

  • Aderolio 1mg
    Sandoz, United Kingdom
  • Aderolio 250µg
    Sandoz, United Kingdom
  • Aderolio 500µg
    Sandoz, United Kingdom
  • Aderolio 750µg
    Sandoz, United Kingdom
  • Afinitor
    Beijing Novartis Pharma Co., Ltd., China; Novartis, Argentina; Novartis, Bosnia & Herzegowina; Novartis, Brazil; Novartis, Chile; Novartis, Colombia; Novartis, Czech Republic; Novartis, Denmark; Novartis, Estonia; Novartis, Egypt; Novartis, Finland; Novartis, Georgia; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Indonesia; Novartis, Ireland; Novartis, Japan; Novartis, South Korea; Novartis, Lithuania; Novartis, Latvia; Novartis, Macedonia; Novartis, Norway; Novartis, New Zealand; Novartis, Poland; Novartis, Portugal; Novartis, Romania; Novartis, Sweden; Novartis, Slovakia; Novartis, Thailand; Novartis, Tunisia; Novartis, Taiwan; Novartis, United States; Novartis AH, South Africa; Novartis Europharm, Belgium; Novartis Europharm, Cyprus; Novartis Europharm, Greece; Novartis Europharm, Slovenia; Novartis Europharm Limited, Iceland; Novartis Farma, Italy; Novartis Farmaceutica, Spain; Novartis Healthcare, Philippines; Novartis ONC, Peru; Novartis Pharma Services, Vietnam; Novartis PHarma Services Inc., Serbia; Novartis Pharmaceuticals, Australia; Novartis Pharmaceuticals, Canada; Novartis Pharmaceuticals UK, United Kingdom; Novartis Singapore, Singapore
  • Afinitor 10
    Novartis, Israel
  • Afinitor 10 mg
    Abacus, Austria; Novartis, France; Novartis, Hungary; Novartis, Oman; Novartis, Turkey; Novartis Europharm, Austria; Novartis Pharma, Switzerland; Novartis Pharma, Germany
  • Afinitor 2,5 mg
    Novartis, France; Novartis, Hungary; Novartis Europharm, Austria; Novartis Pharma, Switzerland; Novartis Pharma, Germany
  • Afinitor 2.5
    Novartis, Israel
  • Afinitor 5
    Novartis, Israel
  • Afinitor 5 mg
    Novartis, France; Novartis, Hungary; Novartis, Oman; Novartis, Turkey; Novartis Europharm, Austria; Novartis Pharma, Switzerland; Novartis Pharma, Germany
  • Afinitor-10
    Novartis, Luxembourg
  • Afinitor-5
    Novartis, Luxembourg
  • Certican
    BModesto, Netherlands; Dr. Fisher Farma, Netherlands; Euro Registratie, Netherlands; Novartis, Argentina; Novartis, Belgium; Novartis, Brazil; Novartis, Chile; Novartis, Colombia; Novartis, Czech Republic; Novartis, Denmark; Novartis, Ecuador; Novartis, Estonia; Novartis, Egypt; Novartis, Finland; Novartis, France; Novartis, Georgia; Novartis, Greece; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Indonesia; Novartis, Ireland; Novartis, Japan; Novartis, South Korea; Novartis, Lebanon; Novartis, Lithuania; Novartis, Latvia; Novartis, Macedonia; Novartis, Mexico; Novartis, Malaysia; Novartis, Netherlands; Novartis, Norway; Novartis, Pakistan; Novartis, Poland; Novartis, Portugal; Novartis, Paraguay; Novartis, Romania; Novartis, Sweden; Novartis, Slovakia; Novartis, Thailand; Novartis, Turkey; Novartis, Taiwan; Novartis, Venezuela; Novartis AH, South Africa; Novartis Farma, Italy; Novartis Farmaceutica, Spain; Novartis Healthcare, Philippines; Novartis Healthcare A/S, Iceland; Novartis PHarma Services Inc., Serbia; Novartis Pharmaceuticals, Australia; Novartis Pharmaceuticals, Cyprus; Novartis Pharmaceuticals, Malta; Novartis Pharmaceuticals UK, United Kingdom; Novartis Trans, Peru; Orifarm, Netherlands
  • Certican 0.1mg
    Novartis, Oman; Novartis Pharma, Bulgaria; Novartis Pharma, Germany
  • Certican 0.25mg
    Novartis, Hungary; Novartis, Israel; Novartis, Luxembourg; Novartis, Oman; Novartis, Uruguay; Novartis Pharma, Austria; Novartis Pharma, Bulgaria; Novartis Pharma, Switzerland; Novartis Pharma, Germany
  • Certican 0.5mg
    Novartis, Hungary; Novartis, Israel; Novartis, Luxembourg; Novartis, Oman; Novartis, Uruguay; Novartis Pharma, Austria; Novartis Pharma, Bulgaria; Novartis Pharma, Switzerland; Novartis Pharma, Germany
  • Certican 0.75mg
    Novartis, Hungary; Novartis, Israel; Novartis, Luxembourg; Novartis, Oman; Novartis, Uruguay; Novartis Pharma, Austria; Novartis Pharma, Bulgaria; Novartis Pharma, Switzerland; Novartis Pharma, Germany
  • Certican 1mg
    Novartis Pharma, Bulgaria; Novartis Pharma, Switzerland; Novartis Pharma, Germany
  • Everolimus
    Dr. Reddy's, United Kingdom; West-Ward, United States; Generics UK, United Kingdom
  • Everolimus Ethypharm
    Ethypharm, United Kingdom
  • Everolimus HCS
    HCS BVBA, United Kingdom
  • Everolimus Novartis
    Novartis, Sweden
  • Everolimus Sandoz
    Sandoz, Australia
  • Everolimus Teva
    Teva, Sweden; Teva Eesti, Estonia
  • Everolimus-Humanity
    BDR Pharmaceuticals, Georgia; Titan, Georgia
  • Linevero
    Ethypharm, United Kingdom
  • Votubia
    Novartis, Belgium; Novartis, Czech Republic; Novartis, Denmark; Novartis, Estonia; Novartis, Finland; Novartis, France; Novartis, Croatia (Hrvatska); Novartis, Lithuania; Novartis, Macedonia; Novartis, Netherlands; Novartis, Norway; Novartis, Poland; Novartis, Portugal; Novartis, Sweden; Novartis, Slovakia; Novartis, Turkey; Novartis Europharm, Cyprus; Novartis Europharm, Greece; Novartis Europharm, Romania; Novartis Europharm Limited, Latvia; Novartis Farmaceutica, Spain; Novartis PHarma Services Inc., Serbia; Novartis Pharmaceuticals UK, United Kingdom; Novartis, Slovenia
  • Votubia 10mg
    Novartis, Hungary; Novartis, Luxembourg; Novartis Europharm, Austria; Novartis Pharma, Germany
  • Votubia 2.5 mg
    Novartis, Hungary; Novartis, Luxembourg; Novartis Europharm, Austria; Novartis Pharma, Switzerland; Novartis Pharma, Germany
  • Votubia 2mg
    Novartis, Luxembourg; Novartis Europharm, Austria; Novartis Pharma, Switzerland; Novartis Pharma, Germany
  • Votubia 3mg
    Novartis, Luxembourg; Novartis Europharm, Austria; Novartis Pharma, Switzerland; Novartis Pharma, Germany
  • Votubia 5mg
    Novartis, Hungary; Novartis, Luxembourg; Novartis Europharm, Austria; Novartis Pharma, Switzerland; Novartis Pharma, Germany
  • Xilcator
    Tuteur, Argentina
  • Zortress
    Novartis, United States

Glossary

TermDefinition
BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide